Advocacy intelligence hub — real-time data for patient organizations
Mayo Clinic — PHASE2
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Epkinly
(epcoritamab-bysp)Orphan drugacceleratedGenmab US, Inc.
Bispecific CD20-directed CD3 T Cell Engager [EPC]
12.1 Mechanism of Action Epcoritamab-bysp is a T-cell engaging bispecific antibody that binds to the CD3 receptor expressed on the surface of T-cells ...
Browse all High grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement news →
Stephen M Ansell, M.D
Dana-Farber - Harvard Cancer Center LAO
📍 ROCHESTER, MN
Reem Karmali, MD, MD
Northwestern University
📍 CHICAGO, IL
Thomas E Witzig, M.D.
Mayo Clinic Health Systems-Mankato
📍 Mankato, Minnesota
View all High grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement specialists →